Close Icon We use cookies to improve your website experience. To learn about our use of cookies and how you can manage your cookie settings, please see our Cookie Policy. By continuing to use the website, you consent to our use of cookies.

Pharma Intelligence is part of the Informa Intelligence Division of Informa PLC

This is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

Products:

Pharma Consulting

Conferences 2020

Awards

Upcoming Webinars

Webinar recordings

Close Icon

Global Search Configuration

Search Site Products & Services
Close Icon

Search by Keyword

Focus
Needs

Get ahead with in-depth pharmaceutical competitive intelligence

Stay on top of the rapidly changing competitive landscape with detailed insight and intelligence on key industry, commercial, clinical, regulatory, and R&D events.

Master the marketplace

To succeed in the pharmaceutical marketplace, it’s vital to stay up to date with developments that can affect your business. Our competitive and market intelligence can give you all the credible, detailed information you need in one place.

What we offer

You can quickly access referenced information across global key industry developments in the pharmaceutical and medical technology markets with our easy-to-use solutions and expert analysts.

Build detailed competitive and market landscape analyses quickly, with access to global information on:

Drug and device development
Patient populations
Clinical trials
Drug and device patents
Market moving events
Patient-based sales forecasts

How it helps

We help you more accurately:

Prioritize pharmaceutical R&D spend by finding gaps and unmet needs through the analysis of competitors’ targets and R&D priorities
Understand disease epidemiology and disease sub-populations targeted in clinical development
Anticipate market changes through patent expiration tracking
Earmark who is entering or exiting your market via licensing or acquisition, as well as who is securing or providing funding
Project revenue for your pipeline and marketed drugs

Relevant products

Datamonitor Healthcare: data analysis and insight

Datamonitor Healthcare's expert coverage of key diseases, companies, drugs and market trends makes it the go-to product for pharmaceutical and biotechnology companies to support the development and validation of their strategic plans and commercial decisions.

Key benefits:

Prioritize market opportunities
Identify unmet needs
Make informed decisions

Biomedtracker: see the drug development process through analysts’ eyes

Real-time tracking and analysis of the drug development pipeline

Key benefits:

Market Events & Catalysts
Likelihood of Approval
Deals Coverage

Scrip: industry news and insights

Key benefits:

Follow market developments
Go beyond the news
Hear from news makers

View all content

Scrip

Coronavirus Update: Regeneron Races Into Phase III Trial Of Antibodies To Block Coronavirus Infection

Plus Updates On Mylan, Sinovac, Zydus Cadila

Topic Coronavirus Clinical Trials Research & Development

View article
Scrip

Operation Warp Speed Spreads Its Bets With 1.6bn Novavax Deal

Novavax has progressed into Phase I trials with relatively little funding, but backing from Operation Warp Speed makes it a stronger contender.

Topic Coronavirus Business Strategies

View article
Scrip

2020 Titans Of Pharma Infographic

Scrip’s eagerly awaited annual snapshot of pharma leadership in 2020 is here. The 2020 Titans of Pharma infographic features key information on the industry’s top leaders and the mega companies they oversee.

Topic Leadership Market Access

View infographic
Scrip

Titans of Pharma 2020: A Bumper Year For Top Executive Compensation

CEO pay at the top 15 pharma companies increased by 3.9% in 2019. But how did that match up to company performance? Read the article now available from Scrip and learn who were the big winners, and how their companies performed financially.

Topic Leadership Company Analysis Market Access

Single report
Datamonitor Healthcare, Biomedtracker

COVID-19 and the impact on the clinical trial space

The effect of COVID-19 on clinical trials, the industry response, and the return to full operations

Topic Coronavirus Clinical Trials

View white paper
Scrip

Pfizer CEO Bourla Wants Profit From COVID-19 Vaccine

Several countries already are calling about orders, as the company prepares to begin a Phase III trial of its mRNA coronavirus vaccine candidate.

Topic Coronavirus Vaccines

View article
Scrip

Gilead Sets Remdesivir Price Commits Nearly All Near-Term Supplies To US

A five-day course will cost $2,340 for governments in developed countries and $3,120 for commercial payers. The US will get 100% of remdesivir manufactured by Gilead in July.

Topic Coronavirus

View article
Citeline, Datamonitor Healthcare

COVID-19 24-hour web event: Lessons learned and a path forward

Join our free 24-hour interactive webinar series on 21 July that will cover the latest insights and learning on COVID-19 from across the global Pharma and Biomedtech industry.

Topic Coronavirus

View interactive data
Scrip

Seizing The Day: How Coronavirus Breaks Then Makes Vaccine Makers In China

Amid fears of a second wave of coronavirus infections and the increasing dominance of state-owned enterprises, private vaccine makers in China are struggling to make the best of the outbreak, BravoVax CEO Ke Wu tells Scrip in an exclusive interview.

Topic Coronavirus Vaccines Clinical Trials

View article
Scrip

CanSino Claims Lead In COVID-19 Vaccine Race And Takes Swipe At Moderna's Ethics

Vaccines veteran calls Moderna ‘shabby’ for lack of transparency and shares sell-off, and flags CanSino’s own forthcoming Phase II results.

Topic Coronavirus Clinical Trials Vaccines

View article
Scrip

Coronavirus Update: CureVac Joins mRNA Vaccines Competitors, Beijing In Lockdown Again

CureVac starts mRNA vaccine trial, Interprotein uses AI in drug discovery and South Korea's Chong Kun and Hanmi make clinical progress.

Topic Coronavirus Vaccines

View article
Scrip

Wary Of Coronavirus Hype And Haste, Themis Looks To Future As Part Of Merck & Co.

Themis’ CEO on how Merck’s commitment to infectious diseases impressed him, and why regulators may not approve suboptimal COVID-19 vaccines.

Topic Coronavirus BioPharmaceutical

View article
Scrip

Coronavirus Update: Will Dexamethasone Breakthrough Make Remdesivir Irrelevant?

The RECOVERY trial has produced clear results for the cheap steroid treatment dexamethasone. What does it mean for Gilead's antiviral remdesivir?

Topic Coronavirus Clinical Trials Company Analysis

View article
Scrip

After Vaccines Row, Sanofi Invests In France, Macron To Secure Supplies

Sanofi’s €610m investment helps row to be forgotten – though Macron will ‘place bets’ on several COVID-19 vaccines, not just France’s homegrown candidate.

Topic Coronavirus Company Analysis

View article
Scrip

COVID-19: The Race To Develop A Vaccine

The world is waiting for a coronavirus vaccine – but can we depend on it, and when will it arrive? A visual tracker of key developments from leading candidates.

Topic Coronavirus

View article